ASIA BEAT: Getting used to bad news
This article was originally published in Scrip
Any outside observer scanning the pharma news flow from Asia over the past few weeks would be justified in concluding the sector to be characterized solely by broad corporate malfeasance or at least alleged wrongdoing in one form or another.
You may also be interested in...
While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.
Japanese firm in discussions with regulator as high-need novel therapy for spinocerebellar degeneration misses endpoint but shows promise in pooled analysis.